A recent 52-week phase 2 study has demonstrated promising results for repetitive transcranial magnetic stimulation (rTMS) as a therapeutic approach in Alzheimer’s disease (AD). This trial applied a targeted, personalized rTMS treatment over the precuneus—a critical area within the brain’s default mode network (DMN)—in patients with mild to moderate AD.
Key findings from this study:
- Targeted Stimulation: The focus on the precuneus leverages its role within the DMN, a network known to be implicated in memory and cognitive function.
- Cognitive and Functional Benefits: rTMS slowed cognitive and functional decline over the 52-week period, suggesting that targeting DMN structures might offer a way to preserve function in AD.
- Potential Mechanisms: rTMS may enhance neural plasticity and modulate brain network activity, though further studies are needed to fully understand the mechanisms involved.
These results underscore rTMS’s potential as a non-invasive intervention that might slow AD progression, with personalization based on brain networks offering a new frontier in treatment approaches for this challenging disease.